Skip to main content
Strategic Partners A/S logo

Strategic Partners A/S — Investor Relations & Filings

Ticker · STRAP ISIN · DK0062502894 LEI · 54930025OZD2GGSQ7L42 CO Financial and insurance activities
Open in API
Filings indexed 501 across all filing types
Latest filing 2022-02-18 Share Issue/Capital Cha…
Country DK Denmark
Listing CO STRAP

About Strategic Partners A/S

https://www.strategic-partners.dk/

Strategic Partners A/S is an investment company that engages in strategic partnerships with businesses that have significant potential. The company's strategy involves taking an active ownership role to create value through its competencies. In addition to its primary focus, the firm may also invest in other equity interests and properties to generate returns. Formerly known as Orphazyme A/S, the company sold its biotechnology activities in May 2022. A new board and management team was appointed in May 2023, and the company officially adopted its new strategy, purpose, and name in October 2024.

Recent filings

Filing Released Lang Actions
Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement detailing a capital increase of 360,000 shares resulting from the utilization of an 'At-the-Market' (ATM) offering program. It explicitly discusses the issuance of new shares, the resulting change in total share capital, and the impact on voting rights. This falls directly under the definition of a share issue or capital change announcement.
2022-02-18 English
Board/Management Information 2022
Board/Management Information Classification · 100% confidence The document is titled "Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO" and explicitly announces the resignation of the CEO and the appointment of the CFO as the new CEO, effective April 1, 2022. This content directly matches the definition for Board/Management Information (MANG), which covers announcements of changes in senior management.
2022-01-31 English
Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO
Board/Management Information Classification · 100% confidence The document is a formal company announcement regarding the resignation of the current CEO and the appointment of a new CEO. This falls directly under the category of changes to senior management.
2022-01-31 English
Earnings Release 2021
Earnings Release Classification · 100% confidence The document is titled "Orphazyme updates 2021 financial outlook" and provides preliminary, unaudited financial figures (Net revenue, Operating expenses, Cash position) for the year ending December 31, 2021. It explicitly states that the audited financial results will be published later (March 15, 2022). This content—a preliminary announcement of key financial results for a period—fits the definition of an Earnings Release (ER), which covers the initial announcement of periodical financial results (key highlights only). It is not the full Annual Report (10-K) or the comprehensive Interim Report (IR), but rather the initial release of the period's performance summary. FY 2021
2022-01-18 English
Orphazyme updates 2021 financial outlook
Earnings Release Classification · 95% confidence The document is a company announcement titled 'Orphazyme updates 2021 financial outlook'. It provides updated guidance on net revenue, operating expenses, and cash position for the fiscal year 2021, ahead of the full audited report. This is a classic 'Earnings Release' or 'Financial Guidance Update' which falls under the Earnings Release (ER) category. While it mentions an attachment, the text itself contains the core financial data and guidance, distinguishing it from a mere report publication announcement. FY 2021
2022-01-18 English
Orphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in Niemann-Pick disease type C
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the outcome of a Type A meeting with the FDA concerning a drug candidate (arimoclomol). It details regulatory interactions, clinical trial endpoints, and future paths for resubmission. As it pertains to significant regulatory developments and legal/regulatory status updates that do not fit into specific financial reporting categories like 10-K or Earnings Releases, it is classified as a Regulatory Filing (RNS).
2021-10-31 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.